CA3104288A1 - Enhanced hat family transposon-mediated gene transfer and associated compositions, systems, and methods - Google Patents

Enhanced hat family transposon-mediated gene transfer and associated compositions, systems, and methods Download PDF

Info

Publication number
CA3104288A1
CA3104288A1 CA3104288A CA3104288A CA3104288A1 CA 3104288 A1 CA3104288 A1 CA 3104288A1 CA 3104288 A CA3104288 A CA 3104288A CA 3104288 A CA3104288 A CA 3104288A CA 3104288 A1 CA3104288 A1 CA 3104288A1
Authority
CA
Canada
Prior art keywords
transposase
seq
sequence
amino acid
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3104288A
Other languages
English (en)
French (fr)
Inventor
David LARGAESPADA
Branden MORIARITY
Beau WEBBER
Neil OTTO
Sandeep Kumar
Leah HOGDAL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
B Mogen Biotechnologies Inc
Original Assignee
B Mogen Biotechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by B Mogen Biotechnologies Inc filed Critical B Mogen Biotechnologies Inc
Publication of CA3104288A1 publication Critical patent/CA3104288A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/90—Vectors containing a transposable element

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
CA3104288A 2018-06-21 2019-06-21 Enhanced hat family transposon-mediated gene transfer and associated compositions, systems, and methods Pending CA3104288A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862688278P 2018-06-21 2018-06-21
US62/688,278 2018-06-21
PCT/US2019/038410 WO2019246486A2 (en) 2018-06-21 2019-06-21 ENHANCED hAT FAMILY TRANSPOSON-MEDIATED GENE TRANSFER AND ASSOCIATED COMPOSITIONS, SYSTEMS, AND METHODS

Publications (1)

Publication Number Publication Date
CA3104288A1 true CA3104288A1 (en) 2019-12-26

Family

ID=67211911

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3104288A Pending CA3104288A1 (en) 2018-06-21 2019-06-21 Enhanced hat family transposon-mediated gene transfer and associated compositions, systems, and methods

Country Status (7)

Country Link
US (1) US11760983B2 (https=)
EP (1) EP3810764A2 (https=)
JP (2) JP2021527427A (https=)
CN (1) CN112543808A (https=)
AU (1) AU2019288669B2 (https=)
CA (1) CA3104288A1 (https=)
WO (1) WO2019246486A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019288669B2 (en) * 2018-06-21 2025-06-26 R&D Systems, Inc. Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods
US20230272355A1 (en) * 2020-06-05 2023-08-31 B-Mogen Biotechnologies, Inc. ENHANCED hAT FAMILY MEMBER SPIN TRANSPOSON-MEDIATED GENE TRANSFER AND ASSOCIATED COMPOSITIONS, SYSTEMS, AND METHODS
CA3201499A1 (en) 2020-11-13 2022-05-19 Catamaran Bio, Inc. Genetically modified natural killer cells and methods of use thereof
WO2022115611A1 (en) 2020-11-25 2022-06-02 Catamaran Bio, Inc. Cellular therapeutics engineered with signal modulators and methods of use thereof
WO2023004366A1 (en) 2021-07-21 2023-01-26 Aspen Neuroscience, Inc. Transposon-based modulation of gba1 and related compositions and uses thereof
WO2023172514A1 (en) 2022-03-07 2023-09-14 Catamaran Bio, Inc. Engineered immune cell therapeutics targeted to her2 and methods of use thereof
JP2025516189A (ja) 2022-04-28 2025-05-27 イマティクス ユーエス，アイエヌシー． 膜結合型ｉｌ－１５、ｃｄ８ポリペプチド、細胞、組成物、およびそれらの使用方法
JP2025515603A (ja) 2022-04-28 2025-05-20 イマティクス ユーエス，アイエヌシー． Ｉｌ－１２ポリペプチド、ｉｌ－１５ポリペプチド、ｉｌ－１８ポリペプチド、ｃｄ８ポリペプチド、それらの組成物、およびそれらの使用方法
JP2025515604A (ja) 2022-04-28 2025-05-20 イマティクス ユーエス，アイエヌシー． ドミナントネガティブＴＧＦβ受容体ポリペプチド、ＣＤ８ポリペプチド、細胞、組成物、およびその使用方法
WO2025054409A1 (en) * 2023-09-07 2025-03-13 Bio-Techne Corporation Mutant tcbuster transposase with improved solubility
WO2025096649A1 (en) 2023-11-01 2025-05-08 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1339863A2 (en) 2000-12-05 2003-09-03 Wisconsin Alumni Research Foundation Double transposition methods for manipulating nucleic acids
US7064246B2 (en) 2001-05-01 2006-06-20 Macrae Amy F Use of transposable elements for altering gene expression
US7262056B2 (en) 2001-11-08 2007-08-28 Mirus Bio Corporation Enhancing intermolecular integration of nucleic acids using integrator complexes
EP1458875A2 (de) 2001-12-20 2004-09-22 Sungene GmbH & Co. KGaA Verfahren zur transformation von pflanzlichen plastiden
ATE498016T1 (de) 2003-02-10 2011-02-15 Max Delbrueck Centrum Transposon-system zur gezielten integration
DK1594973T3 (da) 2003-02-10 2012-02-13 Max Delbrueck Centrum Transposonbaseret målretningssystem
GB2403475B (en) 2003-07-01 2008-02-06 Oxitec Ltd Stable integrands
WO2005062881A2 (en) 2003-12-24 2005-07-14 Transgenrx, Inc. Gene therapy using transposon-based vectors
US20060252140A1 (en) 2005-04-29 2006-11-09 Yant Stephen R Development of a transposon system for site-specific DNA integration in mammalian cells
EP1921140B1 (en) 2005-07-05 2011-12-14 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Mutant transposon vector and use thereof
EP2160461B1 (en) 2007-07-04 2012-08-08 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Hyperactive variants of the transposase protein of the transposon system sleeping beauty
US8524979B2 (en) 2008-04-14 2013-09-03 National Taiwan University Termination of transgene expression via transposon-mediated break
US20110239315A1 (en) 2009-01-12 2011-09-29 Ulla Bonas Modular dna-binding domains and methods of use
WO2010099296A1 (en) 2009-02-26 2010-09-02 Transposagen Biopharmaceuticals, Inc. Hyperactive piggybac transposases
BRPI1010759B1 (pt) 2009-06-11 2019-07-16 Inter-University Research Institute Corporation Research Organization Of Information And Systems Método para produzir uma proteína de interesse ou para obter uma suspensão de células de mamíferos capaz de produzir uma proteína de interesse, bem como vetor de expressão de proteína
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US20130017978A1 (en) 2011-07-11 2013-01-17 Finnzymes Oy Methods and transposon nucleic acids for generating a dna library
WO2013040557A2 (en) 2011-09-16 2013-03-21 The Trustees Of The University Of Pennsylvania Rna engineered t cells for the treatment of cancer
DK3141259T3 (da) 2012-03-15 2019-09-30 Cellectis Repeat-variable direster til targeting af nukleotider
ES2528892T3 (es) 2012-07-30 2015-02-13 Nbe-Therapeutics Llc Identificación mediada por trasposición de proteínas de unión o funcionales específicas
DK3536797T5 (da) 2013-02-01 2024-09-02 Selexis Sa Forhøjet transgenudtrykkelse og -forarbejdning
EP3783098A1 (en) 2013-05-14 2021-02-24 Board Of Regents, The University Of Texas System Human application of engineered chimeric antigen receptor (car) t-cells
CA2943296C (en) 2014-03-21 2022-10-18 The Sydney Children's Hospitals Network (Randwick And Westmead) (Incorporating The Royal Alexandra Hospital For Children) Stable gene transfer to proliferating cells
CN103981204B (zh) 2014-03-24 2016-05-04 上海海洋大学 一种有活性的金鱼Tgf2转座子重组转座酶蛋白的表达方法
US9534234B2 (en) 2014-04-09 2017-01-03 Dna2.0, Inc. Enhanced nucleic acid constructs for eukaryotic gene expression
EP3157328B1 (en) 2014-06-17 2021-08-04 Poseida Therapeutics, Inc. A method for directing proteins to specific loci in the genome and uses thereof
AU2015323973A1 (en) 2014-09-29 2017-04-20 The Jackson Laboratory High efficiency, high throughput generation of genetically modified mammals by electroporation
EP3018200A1 (en) 2014-11-07 2016-05-11 Fondazione Matilde Tettamanti e Menotti de Machi Onlus Improved method for the generation of genetically modified cells
KR20250171479A (ko) 2015-03-31 2025-12-08 소흠, 인코포레이티드 세포 또는 유기체의 게놈으로의 ＤＮＡ 서열의 표적화 혼입을 위한 Ｃａｓ 9 레트로바이러스 인테그라제 시스템 및 Ｃａｓ 9 재조합효소 시스템
ES2926467T3 (es) 2015-04-13 2022-10-26 Maxcyte Inc Métodos y composiciones para la modificación del ADN genómico
US20180087050A1 (en) 2015-05-27 2018-03-29 Jianbiao Zheng Methods of inserting molecular barcodes
EP3929286A1 (en) 2015-06-17 2021-12-29 Poseida Therapeutics, Inc. Compositions and methods for directing proteins to specific loci in the genome
EP3350335B1 (en) 2015-09-16 2019-11-27 T-CURX GmbH Improved transposon system for gene delivery
EP4706680A3 (en) 2015-09-22 2026-03-25 Julius-Maximilians-Universität Würzburg A method for high level and stable gene transfer in lymphocytes
CN105154473B (zh) 2015-09-30 2019-03-01 上海细胞治疗研究院 一种高效安全的转座子整合系统及其用途
EP4289944A3 (en) 2015-10-08 2024-03-13 National University Corporation Tokai National Higher Education and Research System Method for preparing genetically-modified t cells which express chimeric antigen receptor
JP6956416B2 (ja) 2015-12-14 2021-11-02 ゲノムフロンティア セラピューティクス，インコーポレイテッド トランスポゾン系、それを含むキット及びそれらの使用
US20190169602A1 (en) 2016-01-12 2019-06-06 Seqwell, Inc. Compositions and methods for sequencing nucleic acids
KR20190003938A (ko) 2016-02-25 2019-01-10 셀 메디카 스위처란트 아게 면역치료를 위한 변형된 세포
CA3015642A1 (en) 2016-02-26 2017-08-31 Poseida Therapeutics, Inc. Transposon system and methods of use
EP3219800A1 (en) 2016-03-15 2017-09-20 Max-Delbrück-Centrum Für Molekulare Medizin A transposon-based transfection system for primary cells
CN118147079A (zh) 2016-03-31 2024-06-07 来恩生物医药私人有限公司 表达外源病毒特异性t细胞受体(tcr)的非活化t细胞
CA3022267A1 (en) 2016-05-04 2017-11-09 Fred Hutchinson Cancer Research Center Cell-based neoantigen vaccines and uses thereof
CN114891751A (zh) 2016-06-20 2022-08-12 上海细胞治疗研究院 一种高效稳定表达激活型抗体的car-t细胞及其用途
CN107523545A (zh) 2016-06-20 2017-12-29 上海细胞治疗研究院 一种高效稳定表达抗体的杀伤性细胞及其用途
CN107523548A (zh) 2016-06-20 2017-12-29 上海细胞治疗研究院 一种高效稳定表达抗体的t细胞及其用途
CN107523547A (zh) 2016-06-20 2017-12-29 上海细胞治疗研究院 一种高效稳定表达抑制性抗体的car‑t细胞及其用途
KR20190031306A (ko) 2016-07-21 2019-03-25 맥스시티 인코포레이티드 게놈 dna를 변경하기 위한 방법 및 조성물
US11661590B2 (en) 2016-08-09 2023-05-30 President And Fellows Of Harvard College Programmable CAS9-recombinase fusion proteins and uses thereof
EP3508574B1 (en) 2016-08-30 2024-10-09 Kyushu University, National University Corporation Method for inserting desired dna fragment into site located adjacent to binding domain of dna-binding protein
WO2018057779A1 (en) 2016-09-23 2018-03-29 Jianbiao Zheng Compositions of synthetic transposons and methods of use thereof
SG11201901959YA (en) 2016-09-30 2019-04-29 Poseida Therapeutics Inc Modified stem cell memory t cells, methods of making and methods of using same
MA46959A (fr) 2016-12-02 2019-10-09 Juno Therapeutics Inc Cellules b modifiées et compositions et méthodes associées
AU2017378482B2 (en) * 2016-12-16 2024-06-13 R&D Systems, Inc. Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods
KR20190102259A (ko) 2017-01-10 2019-09-03 인트렉손 코포레이션 신규의 유전자 스위치 발현 시스템을 통한 폴리펩티드의 발현 조절
WO2018140644A1 (en) 2017-01-25 2018-08-02 Musc Foundation For Research Development Modified t cells and uses thereof
AU2019288669B2 (en) * 2018-06-21 2025-06-26 R&D Systems, Inc. Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods

Also Published As

Publication number Publication date
EP3810764A2 (en) 2021-04-28
AU2019288669B2 (en) 2025-06-26
JP2021527427A (ja) 2021-10-14
JP7733865B2 (ja) 2025-09-04
JP2024041866A (ja) 2024-03-27
CN112543808A (zh) 2021-03-23
WO2019246486A2 (en) 2019-12-26
AU2019288669A1 (en) 2021-01-21
US20210277366A1 (en) 2021-09-09
US11760983B2 (en) 2023-09-19

Similar Documents

Publication Publication Date Title
US12037611B2 (en) Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods
US11760983B2 (en) Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods
US12097220B2 (en) Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods
CN112195164B (zh) 工程化的Cas效应蛋白及其使用方法
CN115851665B (zh) 工程化的Cas12i核酸酶及其效应蛋白以及用途
CN111712569A (zh) 用于基因编辑的Cpf1-相关方法和组合物
CN114786733A (zh) 由rna-适体募集介导的用于靶向基因组修饰的高效dna碱基编辑器及其用途
JP2025501473A (ja) エンジニアリングされたＣａｓ１２ｂエフェクタータンパク質及びその使用方法
US20230272355A1 (en) ENHANCED hAT FAMILY MEMBER SPIN TRANSPOSON-MEDIATED GENE TRANSFER AND ASSOCIATED COMPOSITIONS, SYSTEMS, AND METHODS
WO2025054409A1 (en) Mutant tcbuster transposase with improved solubility
JP2025518278A (ja) 遺伝子及び細胞療法のためのｔａｌｅ塩基エディター
KR20120112266A (ko) Ｃｍａｈ 유전자를 표적으로 하는 징크 핑거 뉴클레아제 및 이의 용도

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220914

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250124

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250506

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250507

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250613

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250613

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R11-R127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER RECORDAL REQUEST OR RESPONSE

Effective date: 20250626

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250626

R14 Transfer of ownership recorded

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R14-R129 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250708

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250721

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250721

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D149 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S INTERVIEW

Effective date: 20260311

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20260311

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260318

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260318

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260318